Vol 59, No 11 (2003)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Gene therapy of coronary artery disease with phvegf165 - early outcome

Piotr Kołsut, Piotr Żelazny, Anna Teresińska, Bohdan Firek, Przemysław Janik, Zbigniew Religa
Kardiol Pol 2003;59(11):378-383.
Vol 59, No 11 (2003)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background: Gene therapy is a new, experimental method of treatment in patients with coronary artery disease (CAD).
Aim: To determine the safety and efficacy of gene encoding vascular endothelial growth factor (VEGF165) administered directly into the myocardium as the single treatment or combined with coronary artery by-pass grafting (CABG).
Methods: VEGF gene transfer was performed in 22 patients (20 male, 2 female, ages from 48 to 73 years old). A 200 µg of the plasmid encoding VEGF165 was injected into the ischaemic myocardium which could not be surgically revascularised in patients undergoing CABG (n=14), and 400 µg - in patients without CABG (n=8). The value of ejection fraction (EF), myocardial perfusion, angiogram, ventriculography, and nitroglycerine consumption as well as quality of life were evaluated pre- and postoperatively.
Results: The majority of patients had no complications and no fatal outcome was observed. Two patients developed acute myocardial infarction. Left ventricular function values improved and the majority of patients were free from angina 6 months after surgery. Patients reported improved quality of life and a reduction in nitroglycerine usage. A reduction in the ischaemic defects detected by SPECT was also observed. In some patients angiography revealed improved collateral filling.
Conclusions: Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment in patients with chronic and advanced CAD either as a supplementary treatment or as a single therapy.

Abstract

Background: Gene therapy is a new, experimental method of treatment in patients with coronary artery disease (CAD).
Aim: To determine the safety and efficacy of gene encoding vascular endothelial growth factor (VEGF165) administered directly into the myocardium as the single treatment or combined with coronary artery by-pass grafting (CABG).
Methods: VEGF gene transfer was performed in 22 patients (20 male, 2 female, ages from 48 to 73 years old). A 200 µg of the plasmid encoding VEGF165 was injected into the ischaemic myocardium which could not be surgically revascularised in patients undergoing CABG (n=14), and 400 µg - in patients without CABG (n=8). The value of ejection fraction (EF), myocardial perfusion, angiogram, ventriculography, and nitroglycerine consumption as well as quality of life were evaluated pre- and postoperatively.
Results: The majority of patients had no complications and no fatal outcome was observed. Two patients developed acute myocardial infarction. Left ventricular function values improved and the majority of patients were free from angina 6 months after surgery. Patients reported improved quality of life and a reduction in nitroglycerine usage. A reduction in the ischaemic defects detected by SPECT was also observed. In some patients angiography revealed improved collateral filling.
Conclusions: Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment in patients with chronic and advanced CAD either as a supplementary treatment or as a single therapy.
Get Citation

Keywords

gene therapy - coronary artery disease

About this article
Title

Gene therapy of coronary artery disease with phvegf165 - early outcome

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 59, No 11 (2003)

Pages

378-383

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2003;59(11):378-383.

Keywords

gene therapy - coronary artery disease

Authors

Piotr Kołsut
Piotr Żelazny
Anna Teresińska
Bohdan Firek
Przemysław Janik
Zbigniew Religa

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl